TAMPERABILITY/EXTRACTABILITY OF PRESCRIPTION DRUGS

Slides:



Advertisements
Similar presentations
Trend in Prescription Drug Abuse In 2004, 19.1 million Americans were current illicit drug users (7.9% of the U.S. population) 1 In 2004, 19.1 million.
Advertisements

The Who Behind Pharmaceutical Misuse and Abuse – What We Know About Pharmaceutical Abusers Linda Simoni-Wastila, PhD Associate Professor University of.
Drugs as Medicines Coach Graner Health Class Notes.
309: An Overview of Commonly Abused Prescription Drugs.
Topical Bioequivalence Update Robert Lionberger, Ph.D. Office of Generic Drugs.
National Prescription Drug Threat Assessment 2009 National Drug Intelligence Center Drug Enforcement Administration.
Prevalence and Patterns of Nonmedical Use of OxyContin ® and Other Pain Relievers Joe Gfroerer Office of Applied Studies Substance Abuse and Mental Health.
Lock Your Meds BE AWARE. DON'T SHARE.. Your Home Medicine Cabinet: Does it look like this?
Rx for Drug-Seeking Patients in the ED The Monterey County Prescribe Safe Initiative 1.
Pharmacology Application in Athletic Training Michelle Odai, MS, LAT, ATC, CSCS Florida International University.
Controlled Substance Prescribing Trends and Physician and Pharmacy Utilization Patterns: Epidemiological Analysis of the Maine Prescription Monitoring.
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health 1 Regulatory Requirements.
Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.
VINOD P. SHAH, PH.D. SENIOR RESEARCH SCIENTIST OFFICE OF PHARMACEUTICAL SCIENCE CENTER FOR DRUG EVALUATION AND RESEARCH FOOD AND DRUG ADMINISTRATION Pharmacy.
Lock Your Meds BE AWARE. DON'T SHARE. Sponsored by.
Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.
Pharmaceutical Drug Abuse Counterfeit Drugs. Current State of Affairs National drug prevalence studies indicate a sharp increase in prescription drug.
Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.
LEGAL AND ILLEGAL SUBSTANCES. LEGAL DRUGS Legal drugs are considered permissible for use, and are either prescribed by a physician (prescription medications)
Procedure for narcotic drugs use for medical purposes in the Republic of Kazakhstan.
309: Prescription Drug Abuse. The Pennsylvania Child Welfare Resource Center Learning Objectives Participants will be able to: –Associate the history.
Slide 1 Overview of the Drug Formulary Commission and Statutory Objectives Bureau of Health Care Safety and Quality Department of Public Health August.
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
STIMULANTS. What Are They? Defintion: Stimulants are a class of drugs that elevate mood, increase feelings of well-being, and increase energy and alertness.
Abuse Liability and Drug Scheduling: The Role of the FDA Deborah B
Pain Management And Prescribing Controlled Drugs Timothy J. Benedict, RPh Assistant Executive Director Ohio State Board of Pharmacy
Opioid Risk Management Programs Celia Jaffe Winchell, M.D. Acting Deputy Division Director Division of Anesthetic, Critical Care, and Addiction Drug Products.
Drugs as Medicines Coach Graner Health Class Notes.
From the Monitoring the Future Study Report: The University of Michigan 2012.
1 Alcohol and Substance Abuse Council of Jefferson County, Inc. 167 Polk Street, Suite 320 Watertown, New York Voice: ; Fax: ;
An integrated approach to addressing opiate abuse in Maine Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009.
Government and Industry Response to Rx Abuse Robert Bianchi Prescription Drug Research Center - Chicago, IL Atlanta GA - April 7, 2015.
Slide 1 Review of the Drug Formulary Commission Bureau of Health Care Safety and Quality Department of Public Health September 8, 2015.
OR “READ THE FINE PRINT PLEASE!”
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Action Plan for:
H.R Prescription drug abuse prevention and treatment Act of 2011.
Buprenorphine Treatment for Opioid Dependence CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview
The Biopharmaceutical Classification System (BCS)
© 2011 McGraw-Hill Higher Education. All rights reserved. Drug Use: An Overview Chapter 1.
Summary Report and Recommendations on Prescription Drugs: Misuse, Abuse and Dependency Presentation for the County Alcohol and Drug Program Administrators’
Opiate Analgesic Use in Pediatric Patients Bob Rappaport, M.D. Deputy Division Director Division of Anesthetic, Critical Care and Addiction Drug Products,
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.
Analisa Stephens.  NSAID for pain and inflammation reduction ◦ Non-steroidal anti-inflammatory drugs  Localized Pain Patch ◦ Alternative to oral dosage.
OVER THE COUNTER MEDS INTRODUCTION No prescriptions are necessary and no questions need to be answered to attain these drugs OTC med use saves.
미국의 마약류 관리제도 - FDA 와 NIDA 의 조직 및 업무 현황 의약품평가부 이선희.
TAMPERABILITY/EXTRACTABILITY OF PRESCRIPTION DRUGS Robert P. Bianchi PDRC/NMS Labs Drug Delivery Partnership February 8, 2013 San Diego, CA.
DRUGS Prescription, OTC and Supplements. Drugs A drug is a substance other than food that changes the way the body or mind functions. People use drugs.
TAMPERABILITY/EXTRACTABILITY OF PRESCRIPTION DRUGS Robert Bianchi – Prescription Drug Research Center, LLC American Pain Society Meeting – Baltimore, MD.
Drug Enforcement Administration Greater Kansas City Chapter American Society for Pain Management Nursing October 24, 2015 Judy R. Williams Group Supervisor.
Bob Bianchi Prescription Drug Research Center Category 1 Focus Group Meeting Washington DC November,
In vitro - In vivo Correlation
Prescription Drug Monitoring Presented by: Len Abbott, Ph.D. Director Science and Technology Kathleen Valentine, General Manager PDM & Toxicology May 14,
Novel Development of IR Oxycodone HCl Tablets with Aversion ® Technology Kenneth W Sommerville MD Vice President, Clinical Research Robert Rolleri Pharm.
CLINICAL TRIALS.
TAMPERABILITY/EXTRACTABILITY OF PRESCRIPTION DRUGS
Legal and Illegal Drugs
Drug Formulary Commission
Opioids, Synthetics and Cannabis……. OH MY!
- Pharmaceutical Equivalence Study
San Francisco County OBOT Pilot: Pharmacy Aspects
Biopharmaceutics of modified release drug products
Bozeman Health Clinical Research
Prescription Drug Monitoring Program
Can Novel Delivery Systems Deter Rx Drug Abuse?
Government and Industry Response to the US Opioid Epidemic
Survey Results West Hartford High School Risk Behavior Survey – 2017
Presentation transcript:

TAMPERABILITY/EXTRACTABILITY OF PRESCRIPTION DRUGS Pain Therapeutics Summit October 3-4, 2012 San Jose CA TAMPERABILITY/EXTRACTABILITY OF PRESCRIPTION DRUGS Robert P. Bianchi Prescription Drug Research Center - Fairfax, VA

BACKGROUND Prescription drug abuse is the fastest rising category of drug abuse in the US, second only to cannabis and synthetic cannabinoids (ONDCP – Drug Control Strategy 2011). Emergency department visits resulting from non-medical use of prescription analgesics increased 98.4 percent between 2004 and 2009 (NIDA 2011). Seven of the ten substances most abused by high school seniors are legal drugs used non-medically. 2009, Monitoring the Future According to DEA, 17 of the top 25 drugs most often examined by forensic laboratories in 2011, are available as prescription drugs. (DEA, NFLIS, 2011 mid year report)

BACKGROUND An estimated (5%) 10.5 million Americans reported past year use of prescription drugs for non-medical purposes. (National Survey on Drug Use and Health, 2008). Nearly 7 percent of youth between the ages of 12  and 17 (1.7 million) have used such drugs which include pain relievers, sedatives, tranquilizers or stimulants, for non-medical purposes at some point. (National Survey on Drug Use and Health,2008)

BACKGROUND What caused this phenomenon? Prescription drugs do not fall under the clandestine cloud of illegal drugs such as heroin, ecstasy or methamphetamine Prescription drugs are more available due to the development of new products and increased sales Drugs are FDA approved Friends and family use them Drugs are frequently obtained free of cost

TYPES OF ABUSERS* Health care professionals – easy access, educated Hard core opioid addicts – prefers heroin to Rx Casual – low tolerance, alcohol & marijuana Polydrug/Rave – uses anything available Patient abuser – scammer, doctor shopper SR Hard core Rx – converts to IR * Sidney H. Schnoll, MD, PhD

DIVERSION METHODS Doctor shopping or other prescription fraud Illegal online pharmacies Theft and burglary (from residences, pharmacies, etc.) Stereotypical drug dealing (selling pills to others) Receiving from friends or family, often for little or no cost Over prescribing (negligent or intentional over prescribing by physicians)

INFORMATION SOURCES Most abusers do not have technical training and get their information on abuse and extraction methods from friends, publications or the Internet Web sites http://www.courtinfo.ca.gov/opinions/revpub/A100018.DOC http://www.rhodium.ws/chemistry/ http://www.erowid.org/index.shtml http://www.totse.com/en/drugs/speedy_drugs/166004.html http://www.the-hive.ws/forum/forums.pl http://nepenthes.lycaeum.org/Drugs/DXM/extract.html http://www.erowid.org/chemicals/dxm/faq/dxm_chemistry.shtml (good detail) http://www.bluelight.ru/ News group: Alt.drugs, Alt.drugs.hard, Rec.drugs, Lycaeum Amazon.com

INDUSTRY RESPONSE Development of abuse resistant delivery systems Reformulation - Oxycontin Oros® – osmotic pump (POLYOX) Encapsulated pellets Addition of antagonists Capsules within capsules Rel-Ease™ - Ionic complexes Packaging Reservoir transdermal patch Pro-drugs ADPREM Dose counting devices Benefit to industry Enhanced corporate image Fewer litigation actions Increased market share Lower schedule ? – more doctors will prescribe Perceived as safer leading to increased prescriptions Patient/Public Benefit Reduced abuse and subsequent health care costs

SCHEDULING The DEA in concert with FDA has been delegated the authority to add or transfer substances between schedules if the substance has a potential for abuse and meets the criteria for a particular schedule or remove them completely from scheduling Scheduling based on eight factor analysis (combined to major three issues) Potential for abuse and actual pattern of abuse and dependence (combines Factors 1, 4, 5, and 7). Ease of tampering or extracting. Chemistry and pharmacological effect (combines Factors 3 and 2), including whether the substance is an immediate precursor of a controlled substance (Factor 8) Public health risks (Factor 6)

EIGHT FACTORS The 8 factors are specified in the Controlled Substance Act (CSA) as: (1) The drug/substance actual or relative potential for abuse (2) Scientific evidence of the drug/substance pharmacological effect, if known (3) The state of current scientific knowledge regarding the drug/substance (4) The drug/substance history and current pattern of abuse (5) The scope, duration, and significance of abuse (6) What, if any, risk there is to the public health (7) The drug/substance psychic or physiological dependence liability (8) Whether the drug/substance is an immediate precursor of a substance already controlled under this subchapter

ABUSE METHODS Physical – oral, snorting, smoking Multiple doses Heating patches Crushing Chewing Grinding – hammer, coffee grinder, kitchen utensils Removal of barrier – cut patch Extraction –oral, nasal, smoking, IV Solvent extraction to remove excipients and/or concentrate active ingredient

DEFINITIONS Tampering – physical manipulation Crushing Physical separation components (beads, layers, gel) Heating, freezing, crisping, microwaving Extractability – chemical manipulation of a product to remove, concentrate and/or purify the active ingredient performed using commonly available equipment and chemicals Procedures may be used individually or in combination – crushing is frequently the first step in solvent extractions

EXTRACTION EXPERIMENTS Standardized laboratory extractions must be developed for each type of dosage form, e.g. tablets, capsules, patches, liquids, IR, SR using solvents & equipment commonly available. All experiments must be conducted at least in triplicate to provide statistical validity. Controls and a comparator must included.

IN-VITRO EXPERIMENTS aka KITCHEN CHEMISTRY Every product is different; therefore each requires a unique set of experiments to assess tamperability. Sponsor knows product’s vulnerabilities and should develop experiments in concert with abuse experts based on product knowledge and current abuse methods of similar products using commonly available chemicals and equipment. Consider testing all dosage strengths 14

IN-VITRO EXPERIMENTS Develop written protocols that produce statistically valid, reproducible results. Include related comparator product Include controls Include quality assurance procedures Take photographs to illustrate results Use graphs and charts to illustrate data 15

SOLVENT EXTRACTION EXPERIMENTS Information I can share was presented at the American Pain Society annual meeting. Janssen sponsored study to compare the extractability of fentanyl from reservoir and matrix patches. All extractions were performed by NMS Laboratories using chemicals and equipment available to the general public. Identification and purity of extracts confirmed by GC/MS/MS

FENTANYL TRANSDERMAL SYSTEMS The DURAGESIC reservoir patch is a form-fill-seal design that contains a suspension of fentanyl base in a water/ethanol and hydroxyethyl cellulose solution. The matrix patch is a drug-in-adhesive formulation that contains fentanyl base dissolved in an adhesive.

FENTANYL TRANSDERMAL SYSTEMS Generic DURAGESIC® Reservoir Skin Adhesive and Fentanyl Base Backing Layer Backing Layer Fentanyl Base in Gel Rate Controlling Membrane Adhesive Skin

FENTANYL TRANSDERMAL SYSTEMS Products extracted Duragesic® 10 mg/patch – 100μg/hr Matrix 18.4mg/patch -100µg/hr Solvents used Water Vodka (40% ethanol) Bacardi 151 rum Rubbing alcohol (IPA) Vinegar Methyl alcohol

EXTRACTION TECHNIQUES Protective layers removed and intact patches subjected to extraction “Room temperature Soak” (party punch): each patch left undisturbed in 500 ml of each solvent at RT. “Elevated Temperature Soak”: each patch soaked in 500 ml of solvent at boiling point. “3 Hour Percolation”: each patch percolated with 750 ml of each solvent.

ROOM TEMPERATURE SOAK Matrix Duragesic® Methanol Rum IPA Vodka Vinegar Water Duragesic®

IN-VITRO EXPERIMENTS Particle size reduction is generally the first step. Experiments should be attempted at RT and ET as well as after physical manipulation (heating, freezing, microwaving, crisping) Use a variety of available manual and electric tools Set practical time limits (Egalet study- 80% of subjects would spend 3-10 minutes tampering) Smallest particle size generally produces the most desirable result.

SOLVENT EXTRACTION EXPERIMENTS Solvents of different pH and polarity Soaked and stirred RT and elevated temperature (ET) Ground and intact Percolated Single solvent (ingestible e.g. alcohol, water - non-ingestible e.g. paint thinner, acetone) Multiple solvents - aqueous /pH adjustments & immiscible solvents

EXTRACTION EXPERIMENTS All modes of abuse must be considered Oral – the most commonly encountered Nasal – crushing followed by snorting Smoking – crushing/extracting - IV – hard core abusers requiring immediate most intense result

Photos by permission, Egalet, Copenhagen DK, 2010. INJECTABILITY Photos by permission, Egalet, Copenhagen DK, 2010.

Photos by permission, Egalet, Copenhagen, DK 2010. CRISPING Photos by permission, Egalet, Copenhagen, DK 2010. 26

EXTRACTABILITY RATING Neither the DEA nor FDA have objective criteria to measure/evaluate extractability. Ideally, a rating system should be developed that would result in a quantitative score that regulators and industry officials could use to determine the relative extractability of any pharmaceutical product. In February 2012, Dr. Douglas Throckmorton, deputy director of CDER, stated that the FDA will be releasing industry guidance on tamper-resistant formulations by the end of the 2012. 27

EXTRACTABILITY RATING Objective metrics must be established - Number of steps required Amount of equipment and chemicals required Amount of time expended Percent recovery Other active & inactive ingredients recovered Physical characteristics of extract – viscosity, color, odor, syringability

EXTRACTION EXPERIMENTS Although pharmaceutical companies and drug delivery development companies have their own laboratories, the objectivity of an independent laboratory is sought in addition to or instead of in house experiments. FDA guidance to industry recommends that in vitro experiments be conducted by an independent laboratory that is blinded to the fullest extent possible (after the May 2008 advisory committee meeting, FDA advised Purdue to utilize an independent laboratory to conduct in-vitro experiments of reformulated OxyContin).

Summary No objective measure exists to measure Tamperability/extractability Each product/system requires unique experiments designed to address vunerabilities Use independent laboratory & abuse experts Consider all modes of abuse & all strengths Include photographs, graphs & charts where appropriate No product has been proven to be tamper proof

Thank you Robert P. Bianchi Vice-President and Chief of Scientific and Technical affairs Prescription Drug Research Center 134 N. LaSalle Street Chicago, IL 60602 312-726-8620 - Office 571-233-4780 – Cell RBianchi@pdrcllc.com RBConsulting700@AOL.com